Esme Carpenter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Esme Carpenter has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Helen Kakkassery
King’s College London 3 School of Cancer and Pharmaceutical Sciences London, United Kingdom
17 shared publications - Rosalind Graham
King’s College London 3 School of Cancer and Pharmaceutical Sciences London, United Kingdom
17 shared publications - Sheeba Irshad
King’s College London 6 Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences London, United Kingdom
17 shared publications - Thanussuyah Alaguthurai
Department of Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
17 shared publications - Adrian Hayday
Francis Crick Institute, London, UK
13 shared publications - Ashwini Kurshan
Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London SE1 9RT, UK
13 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Supplementary Figure 1: Repeatability of FDG tracer at exploratory timepoints and Predictive Performance of the FLT tracer. A–B. Bland–Altman plots of log-transformed SUV measurements from the two baseline repeatability scans for the FDG tracer at 120 (A) and 180 minutes (B) post-injection. Each point represents an individual lesion. Log SUVmax, SUVmean, SUVpeak and SULpeak are shown. The gray shaded band (log ±0.14) represents the ±15 % variability threshold used to assess test–retest repeatability. C. Individual FDG-PET responses after one cycle of neoadjuvant chemotherapy (NACT) for SUVpeak and SULpeak parameters at 90, 120, and 180 minutes post-injection. Bars are colored by post-cycle 3 MRI response category (complete response, partial response, stable disease, or progressive disease) and annotated according to patient (Pt) number. D. Individual FLT-PET responses for SUVpeak and SULpeak at 90 minutes post-injection. *Patient 7 underwent an early MRI after two cycles due to clinical progression.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Supplementary Figure 1: Repeatability of FDG tracer at exploratory timepoints and Predictive Performance of the FLT tracer. A–B. Bland–Altman plots of log-transformed SUV measurements from the two baseline repeatability scans for the FDG tracer at 120 (A) and 180 minutes (B) post-injection. Each point represents an individual lesion. Log SUVmax, SUVmean, SUVpeak and SULpeak are shown. The gray shaded band (log ±0.14) represents the ±15 % variability threshold used to assess test–retest repeatability. C. Individual FDG-PET responses after one cycle of neoadjuvant chemotherapy (NACT) for SUVpeak and SULpeak parameters at 90, 120, and 180 minutes post-injection. Bars are colored by post-cycle 3 MRI response category (complete response, partial response, stable disease, or progressive disease) and annotated according to patient (Pt) number. D. Individual FLT-PET responses for SUVpeak and SULpeak at 90 minutes post-injection. *Patient 7 underwent an early MRI after two cycles due to clinical progression.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Purpose:Early identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle Patients and Methods:In part A (analytic validity phase), patients with stage II–III TNBC were randomized to FDG or FLT imaging. Baseline repeat scans assessed test–retest repeatability, followed by a post–cycle 1 scan in week 3. Dynamic imaging preceded static acquisitions at 90-, 120-, and 180-minute (FDG) or 90-minute (FLT), evaluating SUVmax, SUVmean, SUVpeak, and SULpeak. Tracer selection for part B was based on prespecified repeatability and response criteria. Part B (clinical validity phase) examined associations between changes in SUV (ΔSUV) after one cycle and post–cycle 3 MRI, end-of-treatment MRI, and residual cancer burden (RCB) at surgery. Exploratory analyses assessed relationships between PET response, Ki-67, and tumor-infiltrating lymphocytes (TIL). Results:Twenty-two patients were enrolled. Both tracers met repeatability thresholds; FDG was selected for part B owing to superior image quality and availability. Fourteen patients underwent FDG-PET across both parts. Reductions in SUVmax/mean after one cycle significantly correlated with mid-treatment MRI response and final RCB score (P < 0.005). Early post–cycle 1 increases in TILs correlated with greater metabolic reduction and lower RCB, whereas Ki-67 changes were not predictive. Conclusions:FDG-PET after one NACT cycle was associated with histologic response and stronger correlations with RCB than MRI. These findings support PET as an early biomarker for treatment response and warrant validation in larger, immunotherapy-era trials.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Purpose:Early identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle Patients and Methods:In part A (analytic validity phase), patients with stage II–III TNBC were randomized to FDG or FLT imaging. Baseline repeat scans assessed test–retest repeatability, followed by a post–cycle 1 scan in week 3. Dynamic imaging preceded static acquisitions at 90-, 120-, and 180-minute (FDG) or 90-minute (FLT), evaluating SUVmax, SUVmean, SUVpeak, and SULpeak. Tracer selection for part B was based on prespecified repeatability and response criteria. Part B (clinical validity phase) examined associations between changes in SUV (ΔSUV) after one cycle and post–cycle 3 MRI, end-of-treatment MRI, and residual cancer burden (RCB) at surgery. Exploratory analyses assessed relationships between PET response, Ki-67, and tumor-infiltrating lymphocytes (TIL). Results:Twenty-two patients were enrolled. Both tracers met repeatability thresholds; FDG was selected for part B owing to superior image quality and availability. Fourteen patients underwent FDG-PET across both parts. Reductions in SUVmax/mean after one cycle significantly correlated with mid-treatment MRI response and final RCB score (P < 0.005). Early post–cycle 1 increases in TILs correlated with greater metabolic reduction and lower RCB, whereas Ki-67 changes were not predictive. Conclusions:FDG-PET after one NACT cycle was associated with histologic response and stronger correlations with RCB than MRI. These findings support PET as an early biomarker for treatment response and warrant validation in larger, immunotherapy-era trials.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF13
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Purpose: Early identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle Patients and Methods: In part A (analytic validity phase), patients with stage II–III TNBC were randomized to FDG or FLT imaging. Baseline repeat scans assessed test–retest repeatability, followed by a post–cycle 1 scan in week 3. Dynamic imaging preceded static acquisitions at 90-, 120-, and 180-minute (FDG) or 90-minute (FLT), evaluating SUVmax, SUVmean, SUVpeak, and SULpeak. Tracer selection for part B was based on prespecified repeatability and response criteria. Part B (clinical validity phase) examined associations between changes in SUV (ΔSUV) after one cycle and post–cycle 3 MRI, end-of-treatment MRI, and residual cancer burden (RCB) at surgery. Exploratory analyses assessed relationships between PET response, Ki-67, and tumor-infiltrating lymphocytes (TIL). Results: Twenty-two patients were enrolled. Both tracers met repeatability thresholds; FDG was selected for part B owing to superior image quality and availability. Fourteen patients underwent FDG-PET across both parts. Reductions in SUVmax/mean after one cycle significantly correlated with mid-treatment MRI response and final RCB score (P < 0.005). Early post–cycle 1 increases in TILs correlated with greater metabolic reduction and lower RCB, whereas Ki-67 changes were not predictive. Conclusions: FDG-PET after one NACT cycle was associated with histologic response and stronger correlations with RCB than MRI. These findings support PET as an early biomarker for treatment response and warrant validation in larger, immunotherapy-era trials.
- 1 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (16) , OF1-OF13
Open AccessA Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Purpose: Early identification of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) can facilitate timely treatment adjustments. This phase II analytic and clinical validity study (TNPET01) evaluated whether [18F]-fluorodeoxyglucose (FDG) or [18F]-fluorothymidine (FLT) positron emission tomography (PET)/CT can predict response after one NACT cycle Patients and Methods: In part A (analytic validity phase), patients with stage II–III TNBC were randomized to FDG or FLT imaging. Baseline repeat scans assessed test–retest repeatability, followed by a post–cycle 1 scan in week 3. Dynamic imaging preceded static acquisitions at 90-, 120-, and 180-minute (FDG) or 90-minute (FLT), evaluating SUVmax, SUVmean, SUVpeak, and SULpeak. Tracer selection for part B was based on prespecified repeatability and response criteria. Part B (clinical validity phase) examined associations between changes in SUV (ΔSUV) after one cycle and post–cycle 3 MRI, end-of-treatment MRI, and residual cancer burden (RCB) at surgery. Exploratory analyses assessed relationships between PET response, Ki-67, and tumor-infiltrating lymphocytes (TIL). Results: Twenty-two patients were enrolled. Both tracers met repeatability thresholds; FDG was selected for part B owing to superior image quality and availability. Fourteen patients underwent FDG-PET across both parts. Reductions in SUVmax/mean after one cycle significantly correlated with mid-treatment MRI response and final RCB score (P < 0.005). Early post–cycle 1 increases in TILs correlated with greater metabolic reduction and lower RCB, whereas Ki-67 changes were not predictive. Conclusions: FDG-PET after one NACT cycle was associated with histologic response and stronger correlations with RCB than MRI. These findings support PET as an early biomarker for treatment response and warrant validation in larger, immunotherapy-era trials.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S1. Waning serological responses to SARS-CoV-2 vaccination.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S1. Waning serological responses to SARS-CoV-2 vaccination.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S3. Boosted serological responses and persistent T cell responses following SARS-CoV-2 vaccination dose
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S3. Boosted serological responses and persistent T cell responses following SARS-CoV-2 vaccination dose